The grades of four Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Novartis (NYSE:NVS) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Novartis manufactures pharmaceutical and consumer healthcare products. The stock has a dividend yield of 2.5%. For more information, get Portfolio Grader’s complete analysis of NVS stock.
Mylan (NASDAQ:MYL) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Mylan is a global generic and specialty pharmaceuticals company. Shares of MYL have increased 8.3% over the past month, better than the 8.5% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of MYL stock.
Pacira Pharmaceuticals (NASDAQ:PCRX) improves from a B to a A rating this week. Pacira Pharmaceuticals is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of PCRX stock.
Acura Pharmaceuticals (NASDAQ:ACUR) shows solid improvement this week. The company’s rating rises from a C to a B. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.